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Progress toward the Development of an Implantable Sensor for Glucose
George S. Wilson,1 Yanan Zhang,1 Gérard Reach,2 Dinah Moatti-Sirat,2 Vincent Poitout,2 Daniel R. Thévenot,3
Fabrice Lemonnier,4 and Jean-Claude Klein4
The development of an electrochemically based implant¬
able sensor for glucose is described. The sensor is
needle-shaped, about the size of a 28-gauge needle. It is
flexible and must be implanted subcutaneously by using a
21-gauge catheter, which is then removed. When com¬
bined with a monitoring unit, this device, based on the
glucose oxidase-catalyzed oxidation of glucose, reliably
monitors glucose concentrations for as long as 10 days in
rats. Various design considerations, including the deci¬
sion to monitor the hydrogen peroxide produced in the
enzymatic reaction, are discussed. Glucose constitutes
the most important future target analyte for continuous
monitoring, but the basic methodology developed for
glucose could be applied to several other analytes such
as lactate or ascorbate. The success in implementation of
such a device depends on a reaction of the tissue
surrounding the implant so as not to interfere with the
proper functioning of the sensor. Histochemical evidence
indicates that the tissue response leads to enhanced
sensor performance.
Additional Keyphrases: enzyme electrode • glucose oxidase •
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Determination of concentrations of glucose in blood
has long been recognized as an important clinical diag¬
nostic test for diabetes. Thirty years ago, Clark and
Lyons (1 ) suggested coupling an enzymatic reaction to
electrochemical monitoring in what was subsequently
called an enzyme electrode. This device made possible
the largely selective detection of glucose in both serum
and whole blood, and commercially available clinical
analyzers from Yellow Springs Instruments and Beck-
man Instruments, among others, have been available
for some time. A significant breakthrough occurred in
the early 1980s, when self-monitoring of blood glucose
became possible through the development of dry chem¬
ical strips for use with a single drop of blood. The
resulting reaction (again, typically involving the glu¬
cose oxidase-catalyzed oxidation of glucose) could be
followed by monitoring the formation of product spec-
trophotometrically or electrochemically. More recently,
the possibility of monitoring glucose by noninvasive
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near-infrared techniques has been proposed (2, 3). This
procedure would eliminate the painful and annoying
step of pricking the finger to obtain blood.
Although self-monitoring is considered a major ad¬
vance in diabetes management, it is limited practically
by the number of determinations a patient can reason¬
ably be expected to make in a 24-h period. Most patients
complain that making these measurements is boring
and inconvenient, and they are not willing to take more
than two or three measurements a day. Such a sampling
frequency does not permit tight control of blood glyce-
mia at values close to normal [(—1.00 g/L (5.5 mmol/L)]
throughout the day. Normoglycemia research is ham¬
pered by the fact that induced hypoglycemia will occur,
leading possibly to convulsions or loss of consciousness.
This concern influences a strategy that, in the absence
of reliable monitoring, results in control of glycemia at
glucose concentrations well above normal. The interim
results from the Diabetes Control and Complication
Trial (DCCT) (4 ) suggest that chronically high concen¬
trations of blood glucose are at least partly responsible
for such subsequent complications as blindness or end-
stage renal failure. Improved glycémie control has been
demonstrated when monitoring is based on measure¬
ments of glycohemoglobin, but it is unlikely that the
normal range can be reached without careful and con¬
tinuous monitoring of glucose (5).
Accordingly, a strong argument can be made for the
need of a continuous glucose monitoring system that is
reliable, portable, and inconspicuous. Such a system
would acquire time-dependent glycemia data that could
be used by the physician as an aid in normalizing
insulin therapy for a particular patient. It would also
provide an alarm system to warn the patient when
glucose values fall or are about to fall outside of the
desired range. Ultimately, if the glucose sensor proved
highly reliable, then perhaps its coupling to an insulin
pump could be considered as an approach to the artifi¬
cial pancreas.
Approaches to Glucose Sensing
In the early 1970s, attempts were made to develop
systems for the automatic control of blood glucose con¬
centrations, the best known of these being the Biosta-
tor® (Miles Labs., Elkhart, IN). This system requires
external circulation of blood into a detection chamber,
where the blood is diluted before being measured with
an enzyme electrode. Insulin is then infused on the basis
of the measured glucose concentrations. Unfortunately,
this system requires catheterization, heparinization,
and dilution of blood and is therefore useful only in a
clinical setting. Further, the system is so bulky as to be
CLINICAL CHEMISTRY, Vol. 38, No. 9, 1992 1613
useless for an ambulatory patient. Most important,
however, is the lack of a sensor that can function
reliably long term.
It is now well established that the concentration of
blood glucose is the analyte ofmerit for diabetes man¬
agement, therefore, direct monitoring of blood glucose
should be the approach of choice. It is necessary, how¬
ever, to balance the benefits of continuous monitoring
against the risk of infection or blood clotting, which
might result from implanting a sensor in the vascular
bed. Thus, even though the feasibility of long-term
monitoring has been demonstrated in dogs (6), it is
unlikely that this approach would be readily accepted in
humans. Two other sampling sites have been investi¬
gated in detail: the peritoneal cavity {7,8) and subcu¬
taneous tissue (9-16). Sensors implanted in the former
site show rapid changes in glucose concentrations that
correlate well with those in the blood (27). The utiliza¬
tion of this site would require surgical implantation and
thus would dictate long-term sensor reliability, proba¬
bly for several years or more. Not only would the sensor
have to be implanted but also the monitoring unit.
Such considerations have led to the focus on the
subcutaneous tissue as the site of choice. Several recent
studies (15,16) have established that the subcutaneous
glucose concentrations are the same as the concentra¬
tions in blood, but the former lag behind rapid changes
in blood glucose by ~5 min (18). The possibility ofusing
subcutaneous monitoring as part of a closed-loop insulin
delivery system has been demonstrated in diabetic dogs
(17). Minimally invasive, this approach permits the
sensor to be connected to a monitoring unit the size of a
wristwatch. Several subcutaneous implantation sites
are feasible, and such a sensor/monitoring unit combi¬
nation would meet the requirements of a small unob¬
trusive continuous glucose monitoring system.
Fundamentals of Sensor Operation
By the early 1980s, the enzyme electrode had proven
its capabilities in the in vitro measurement of blood or
serum glucose, but in vivo measurements proved much
more difficult. It was not possible to simply scale down a
0.2- to 2-cm (o.d.) sensor to a size that would be compat¬
ible with subcutaneous implantation. Nevertheless,
Shichiri et al. (9) demonstrated that a needle-type
sensor could be used for such measurements. For ease of
implantation and for minimal pain associated with this
process, the diameter of a practical sensor would have to
be <0.5 mm, ideally —0.35 mm (the size of a 28-gauge
needle).
Practically all of the reported sensors with which
continuous measurements have been made are electro-
chemically based and take advantage of the reaction of
glucose with oxygen:
Glucose + O2 —> gluconic acid + H2O2
This reaction can be monitored by following either the
consumption of oxygen (Figure LA ) or the formation of








Fig. 1. Detection approaches for the glucose enzyme electrode:
detection based on (A) oxygen; (8) peroxide; and (C) a mediator
Red and Ox correspond to the reduced and oxidized forms of the mediator,
respectively; FAD and FADH2 are the oxidized and reduced forms of the
flavoenzyme prosthetic group. Adapted with permission from reference 19
has the advantage that the oxygen can be electrochem-
ically detected by simply putting a gas-permeable mem¬
brane in front of the electrode. The membrane excludes
various electroactive endogenous molecules. However,
because the rate of the reaction depends on the con¬
sumption of oxygen, it is necessary to measure the
difference between the incoming oxygen flux and that
which arrives at the electrode. Such an arrangement is
intrinsically complicated, particularly for the very small
sensor specified above. The second and most widely
applied method involves detection of a product of the
enzymatic reaction. This approach does not require a
difference measurement but, because of the relatively
high applied potential necessary to monitor hydrogen
peroxide, interference from endogenous electroactive
species such as urate and ascorbate must be considered.
A third method (Figure 1C) involves the use ofmedi¬
ators placed in the enzyme layer; these couple the
oxidation of reduced enzyme to the electrode because it
is not possible to carry out efficient and direct electro¬
chemical oxidation of the enzyme. The mediator, in
principle, replaces oxygen in the above reaction, func¬
tioning as the electron acceptor. The applied potential
can often be much lower than in the second method
(Figure LB), so that interference from endogenous spe¬
cies can often be eliminated. However, because oxygen
can freely diffuse throughout the enzyme layer and the
mediator typically cannot, the ability of the mediator to
compete with oxygen is often poor. This leads to a












Fig. 2. Diagram of the multilayered sensing element, showing the
fluxes of the various species present
GOx, glucose oxidase; glu~, reduced glucose
it by using a short (3 cm) stainless steel catheter (21
gauge), which is removed after the sensor is in place.
Because of the high applied potential necessary to
detect peroxide (650 mV vs the Ag/AgCl reference
electrode), the influence of endogenous electroactive
species must be considered. Species such as urate and
ascorbate are anionic and accordingly are retarded by
the negatively charged inner membrane (cellulose ace¬
tate); therefore, they do not constitute a significant
interference (20). Neutral molecules such as acetami¬
nophen (paracetamol) are not retarded by the inner
membrane layer; therefore, an additional polymer layer
has been added. Preliminary in vivo studies support the
effectiveness of this additional layer (unpublished re¬
sults).
parasitic influence of oxygen on the response. If the
mediator is made more mobile, it escapes out of the
enzyme layer into the biological medium. The use of
mediators in sensors with good long-term stability will
probably depend on the construction of very stable but
very thin enzyme layers that contain fixed mediator
sites. Work in this direction is proceeding in several
laboratories.
The role of the outer membrane (Figure 2) is ex¬
tremely important to sensor function. Proper adjust¬
ment of the permeability of this membrane to glucose
renders the rate of the enzymatic reaction linearly
dependent on the external glucose concentration up to
—15 mmol/L. In the case of our sensor (20), the use of
polyurethane as the outer membrane significantly re¬
duces the flux of glucose without materially affecting
that of oxygen. The result is a sensor that depends on
oxygen for its function but for which the response is
nevertheless essentially oxygen independent. At 15
mmol/L glucose concentration, a properly prepared sen¬
sor will show <5% decrease in response as P 02 passes
from 120 to 1 kPa (21 ). At basal values, oxygen depen¬
dence is even less (the normal tissue content ofoxygen is
estimated at 2.7-3.3 kPa). The outer membrane also
serves to protect the enzyme layer from the biological
fluid, preventing the destruction of peroxide by, e.g.,
endogenous catalase. The outer membrane also inter¬
acts with the tissue, a process with an important influ¬
ence on sensor function (discussed later). The entire
sensor in its current form is shown in Figure 3. Its
overall length is 4 cm, the diameter of the sensing
element is 250 mm, and the overall diameter at the
widest point (reference electrode) is 350 mm. This cor¬
responds to the outside diameter of a 28-gauge needle.
Because the sensor is extremely flexible, we can implant
In Vivo Evaluation of Sensor Performance
A key element in evaluation in vivo is the establish¬
ment in situ of the relationship between the blood
glucose concentration and the sensor response. This is
accomplished by increasing the blood glucose concentra¬
tion in normal animals such as dogs or rats by venous
infusion (22) or by intraperitoneal injection (23), respec¬
tively, of glucose. The sensor response is measured at t
= 0 (baseline) and again at a plateau of>5min after the
effect of the infusion is seen. At each of these points, the
concentration of blood glucose is measured by using,
e.g., the Beckman Analyzer or a self-monitoring strip.
From this information, one can then establish the slope
(sensitivity) and the intercept (background current)
(24). This procedure provides a reliable calibration
curve without having to assume that the in vitro and in
vivo responses are the same. This procedure has been
described elsewhere (18, 24).
Long-term sensor response has been evaluated in rats
over the first 10 days after implantation (23). When the
sensor is initially implanted, there is a period of 2-4 h
during which the sensor response stabilizes. From day 1
to day 10, there is essentially no change in either the
sensitivity or the apparent response time of the sensors
(n = 7). We consider this an important finding and
suggest that previous observations led to overly pessi¬
mistic conclusions. The small size of this sensor and the
minimal tissue damage caused by its implantation may
contribute to its superior performance.
We evaluated the performance of the sensors (23)
after 10 days, using the error grid analysis method of
Clarke et al. (25) shown in Figure 4 (n = 101). All
sensor-measured values fell in zone A (clinically accu¬
rate), except for one value in zone B (clinically accept¬
able). The points below the correlation line are gener¬
ally a manifestation of the lag time because the blood
glucose concentrations increase faster than the subcu¬
taneous ones. When glycemia is decreasing, the reverse
is the case, and the sensor values lie above the correla¬
tion line. The lag time is due to the kinetics of glucose
infusion and is not limited by the intrinsic sensor
response time. These results show that, even if the effect
of the lag time is ignored, there is no adverse effect on
PU Layer Ag/AgCl Reference
Teflon pt_|r wire
Fig. 3. Diagram of the implantable sensor
PU, polyurethane
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Fig. 4. Error grid analysis for estimating the accuracy of sensor-
generated blood glucose values, 10 days after implantation
The plot is divided into five zones (A-E) on the basis of the clinical significance
of the glycemia estimated by the sensor. A: estimation clinically accurate; B:
acceptable estimation; C: inaccurate estimation; D,E: decision based on these
estimations would lead to potentially hazardous decision (e.g., injecting insulin
when glycemia is actually low). Reprinted from reference 23 with permission
the clinical conclusions derived from sensor measure¬
ments.
The implementation of the continuous monitoring
system requires a unit that can maintain the appropri¬
ate applied potential between the indicating and refer¬
ence electrodes while measuring the resulting current.
The time-dependent fluctuations of this current are
stored and transformed into an estimation of the blood
glucose concentration. Such a system has been designed
and constructed at the Ecole des Mines de Paris and is
currently being evaluated. For practical application, the
monitoring unit must be miniaturized to be compatible
with its use as a wearable system.
Biocompatibility and Biostability
The subcutaneous implantation of the sensor would
reasonably be expected to produce a tissue response.
Indeed, histological examination of the implant after 3
days showed the formation of fibrovascular tissue
around the site of implantation, accompanied by a few
macrophages, plasma cells, and polymorphonuclear
cells (23). There was also evidence of neovasculariza¬
tion, which might serve to improve delivery of glucose
and oxygen to the sensor surface. Previous studies have
shown that the sensor is not toxic (26). Thus the sensor
is not inert, but elicits a tissue response that actually
improves sensor performance by regenerating the oxy¬
gen and glucose delivery system.
It is not yet known how long such sensors might be
implanted in humans, the clinical studies of this having
just begun. Experience with transdermal implantation
of catheters suggests that 5-7 days would be the maxi¬
mum, provided that care is taken to keep the penetra¬
tion region sterile. This period of time should be ade¬
quate: implantation of the sensor by the patient is a
simple task, and the sensor could be changed regularly.
Future Prospects
A few analytes have been identified as important
targets for continuous monitoring in humans. Most of
these are measured only in critical-care situations:
blood gases, pH, Na+, K+, etc. Most other analytes are
more efficiently handled as batch samples. Future tar¬
gets will undoubtedly be identified according to the
following criteria: (a) Is it feasible to monitor the target
analyte? (b) Is it clinically useful to continuously mea¬
sure this analyte? (c) Is there a sufficiently large market
for a monitoring system to justify the necessary re¬
search and development? So far, only glucose meets
these requirements—although continuous monitoring
of K+ or urea during hemodialysis might prove useful.
We have recently developed an analogous in vivo sensor
for lactate (27) that may be useful for monitoring
localized lactate concentrations—perhaps during car¬
diac surgery (however, even the medical usefulness of
this measurement has been questioned). It may eventu¬
ally be possible to monitor therapeutic drugs that have
a narrow therapeutic range, especially those that might
be infused at a controlled rate. If patients are going to
use these monitoring systems themselves, the systems
must be simple and inexpensive. More probable is the
development of in vivo enzyme electrode sensors for
neuroactive substances, especially those that are not
intrinsically electroactive (28). Such applications will
probably be confined to the neuroscience research labo¬
ratory.
A fundamental question is whether the sensor, which
must necessarily be quite small, is properly sampling
the site of implantation and also whether this site is
indicative of the region of interest. Sensors based on
amperometric detection (such as glucose) are typically
coupled to an enzyme that catalyzes an oxidation-
reduction reaction. The analyte provides one of the
necessary redox couples; the other, which will be con¬
sumed in the reaction, must also be provided. This is the
reason why oxidases have been so widely used: oxygen is
almost always present. A very large group of enzymes
use the NAD+/NADH couple as a coenzyme; however,
this couple is used very little in enzyme electrode
applications because the coenzyme, which functions as a
mediator, has many of the limitations of the mediator
described above.
Clearly, if reliable, low-cost, noninvasive sensors can
be developed, they will be the approach of choice. In the
interim, minimally invasive devices may fill a critical
gap.
This work is supported in part by the National Institutes of
Health (DK30718) and the Institut National de la Santé et de la
Recherche Médicale.
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